By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel consensus is bearish on BSX, with key risks including Watchman's growth stagnation and potential reimbursement headwinds, and the company's reliance on Watchman recovery for future growth.
Risk: Watchman's growth stagnation and potential reimbursement headwinds
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
With a forward P/E of 14.45x and upside potential of 59.60%, Boston Scientific Corporation (NYSE:BSX) ranks among the top 10 lowest forward P/E stocks in the S&P 500.
A dose bottle of the medication is in the medical tech's hand
Boston Scientific Corporation (NYSE:BSX) has seen a sharp de-rating in 2026, with shares down nearly 50% year-to-date as of June 8, 2026, even as the vast majority of covering analysts maintain bullish ratings on the stock.
The pressure point is Boston Scientific Corporation (NYSE:BSX)’s Watchman left atrial appendage closure franchise, where management recently signaled reduced growth expectations over the next couple of quarters.
On June 3, 2026, BTIG analyst Marie Thibault cut the firm’s price target on Boston Scientific Corporation (NYSE:BSX) to $65 from $80, keeping a “Buy” rating, after updating the firm’s forecast to reflect those comments, made at a sell-side conference. BTIG said visibility is limited for now and framed its stance as cautious, modeling flattish Watchman sales in the second and third quarters, a slight sequential uptick in the fourth quarter, and a mild, gradual recovery through 2027.
On June 1, 2026, Canaccord also trimmed its price target, to $70 from $71, while keeping a “Buy” rating. The firm updated its model to account for Watchman slowdowns in both 2026 and 2027, which it said carry negative implications for its revenue and EPS estimates.
Despite the target cuts, both firms held their bullish ratings, reflecting the broader Wall Street view on Boston Scientific Corporation (NYSE:BSX).
Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.
While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
Four leading AI models discuss this article
"The sole driver of a durable BSX rally is a credible, sustained rebound in Watchman LAAC adoption; without that, valuation re-rating is unlikely."
BSX trades at ~14.5x forward earnings with a potential ~60% upside per BTIG’s model, but the bull case rests on a back-end recovery in Watchman LAAC adoption. The 50% YTD drop indicates investors are already pricing in substantial risk from near-term growth disappointment and potential reimbursement or implantation-rate headwinds. The article glosses over Watchman’s contribution risk—if growth stalls through 2027, the valuation multiple likely contracts even if EPS stabilizes in other segments. Also, a relatively slow pipeline, competition in LAAC devices, and macro hospital spending cycles could cap upside. An investor should test sensitivity to Watchman revenue input and consider regulatory/reimbursement hurdles.
The strongest case against your bullish take is that Watchman growth may never recover to support a 60% upside. The rest of BSX's businesses are modest, so further delays or reimbursement headwinds could trigger a material multiple reset.
"The market is incorrectly pricing a temporary franchise headwind as a fundamental impairment of Boston Scientific's diversified med-tech business model."
The 50% YTD sell-off in BSX is a classic overreaction to a localized growth deceleration in the Watchman franchise. While the market is pricing in structural failure, this is likely a transitory hurdle. At a 14.45x forward P/E, the stock is being treated like a distressed asset rather than a diversified med-tech leader with robust exposure to high-growth areas like neuromodulation and structural heart. The street's obsession with Watchman visibility ignores the broader portfolio's resilience. If the company can stabilize guidance in Q3, the current valuation provides an asymmetric entry point, as the market is currently ignoring the underlying margin expansion potential of their MedSurg segment.
The sharp de-rating suggests the market is pricing in a permanent loss of market share to emerging competitors in the LAA closure space, meaning the 'transitory' slowdown could actually be a terminal decline in a key high-margin growth driver.
"A 14.45x forward P/E on guidance for flattish growth in your largest growth driver is not a valuation opportunity—it's a warning sign that consensus is underestimating either competitive erosion or demand saturation in Watchman."
BSX is trading at 14.45x forward P/E with a 50% YTD drawdown, but the article conflates valuation cheapness with investment merit. The real issue: Watchman LAA closure—likely 20-30% of cardiovascular revenue—faces multi-quarter stagnation per management guidance. BTIG cut its target 19% ($80→$65) while keeping 'Buy,' which is internally inconsistent; if Watchman recovers only 'mildly' through 2027, the $65 target itself looks optimistic. The article offers zero detail on why Watchman slowed (competitive pressure? reimbursement? clinical adoption plateau?) or whether other segments can offset it. A 14.45x multiple on a company guiding flattish growth in its marquee franchise isn't a bargain—it's a value trap.
If Watchman's slowdown is temporary (FDA label expansion, international rollout delays, inventory normalization) rather than structural, the stock could re-rate sharply; at 14.45x with 59% upside, the market is pricing in worse-case assumptions, creating asymmetric risk/reward.
"The magnitude of recent price-target cuts reveals more durable Watchman risk than the retained Buy ratings suggest."
The article frames BTIG's Buy rating and 14.45x forward P/E as supportive for BSX, yet glosses over the scale of the June 3 target cut from $80 to $65 after Watchman guidance was lowered. This 19% reduction, paired with Canaccord's trim and the stock's 50% YTD drop through June 2026, indicates the market is pricing in sustained pressure on the left atrial appendage closure business that extends beyond the modeled flattish Q2-Q3 sales. The Cardiovascular segment's reliance on Watchman recovery through 2027 leaves limited cushion if reimbursement scrutiny or competitive entrants accelerate. Broader MedSurg diversification is cited but not quantified against the specific Watchman headwind.
Watchman may prove only a temporary pause while other Cardiology and Peripheral Interventions products deliver above-consensus growth, allowing BSX to re-rate higher once visibility improves in 2027.
"Watchman risk is not a temporary hiccup; if Watchman misses again and reimbursement headwinds persist, BSX’s upside will depend on core segments that may not fully compensate, risking a deeper re-rating than currently priced."
Watchman is the obvious stress test, but Grok's take underplays how vulnerable the rest of the portfolio is to margin and reimbursement risk. The 19% cut signals more than a temporary deceleration; if Watchman misses again, the implied re-rate could extend beyond 2027. The market's 14.5x multiple already prices a cash-generative, low-growth core; any further deterioration could push BSX back into mid-teens earnings, not a multi-year upside.
"The market is not mispricing a temporary slowdown; it is accurately discounting the terminal value of a core franchise facing structural competitive erosion."
Gemini, your 'asymmetric entry' thesis ignores the capital allocation reality: if Watchman growth is terminal, BSX cannot simply pivot to MedSurg as a growth engine. MedSurg is a mature, high-competition segment with lower margin expansion potential than the high-acuity cardiovascular space. You're assuming a 'transitory' hurdle without accounting for the massive R&D spend required to defend market share against Abbott’s Amulet. At 14.5x, you're paying for a shrinking moat, not a diversified leader.
"BTIG's Buy rating at a 19% lower target is only credible if 'mild' Watchman recovery is explicitly modeled—otherwise it's a cover for structural deterioration."
Claude and Grok both flag the internal inconsistency in BTIG's $65 target under 'mild' Watchman recovery, but neither quantifies what 'mild' means. If Watchman revenue grows 5-8% through 2027 instead of the pre-2024 double-digit pace, does that support $65 or not? The target cut from $80 suggests the analyst no longer believes even mild recovery; that's a buried capitulation, not a Buy signal. Without that math, we're guessing whether 14.5x is cheap or a trap.
"BTIG's cut already embeds low-single-digit Watchman growth but ignores potential Cardiovascular margin spillover from LAAC competition."
Claude correctly flags the need to quantify 'mild' Watchman growth at 5-8%, yet this still overlooks spillover reimbursement risk to the broader Cardiovascular segment. CMS scrutiny on structural heart procedures could compress margins 150-200bps by 2027 even if MedSurg holds steady, an outcome the $65 target implicitly prices but the article never tests. Without segment-level sensitivity tables, 14.45x remains more trap than entry.
The panel consensus is bearish on BSX, with key risks including Watchman's growth stagnation and potential reimbursement headwinds, and the company's reliance on Watchman recovery for future growth.
Watchman's growth stagnation and potential reimbursement headwinds